Gilead Sciences just paid $11.9 billion to acquire Kite Pharma. At $180 a share, that price represents a 29.4 percent premium over Kite's closing share price on Friday, according to Reuters.
...and receive Daily News bulletins.
Already have an account?Login Now.
Magdalena Skipper, the incoming editor-in-chief of Nature, speaks with NPR's Weekend Edition Sunday.
Genetic genealogy has led to an arrest in another cold case, dating back to 1987.
In PLOS this week: mutation in second gene widens clinical symptoms of people with ADD3 mutations, comparative genomic analysis of Pseudovibrio, and more.
Wired reports that 23andMe is trying to bolster its outside collaborations.